Purple Biotech (PPBT) Total Liabilities (2014 - 2026)

Purple Biotech (PPBT) has 11 years of Total Liabilities data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Total Liabilities changed N/A year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (changed N/A YoY) and the FY2025 annual result came in at $7.9 million, up 90.4% from the prior year.
• Total Liabilities declined to $4.7 million in Q1 2026 per PPBT's latest filing, from $7.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $10.0 million in Q4 2023 and bottomed at $4.1 million in Q4 2024.
• The 5-year median for Total Liabilities is $7.5 million (2022), against an average of $6.8 million.
• The widest annual swing landed in 2024, when Total Liabilities plunged 58.75%; it then surged 90.4% in 2025.
• Tracing PPBT's Total Liabilities over 5 years: stood at $7.5 million in 2022, then surged by 32.97% to $10.0 million in 2023, then sank by 58.75% to $4.1 million in 2024, then surged by 90.4% to $7.9 million in 2025, then plunged by 40.25% to $4.7 million in 2026.
• Per Business Quant, the three latest PPBT Total Liabilities figures stand at $4.7 million (Q1 2026), $7.9 million (Q4 2025), and $4.1 million (Q4 2024).

Peer Comparison